Latest Breaking News On - சுகாதாரம் மெய்நிகர் மாநாடு - Page 3 : vimarsana.com

About Polyphor Polyphor is a research driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please

Switzerland generalGokhan baturHernan levettMary ann changBernhard schmidPolyphor ltdSwiss exchangeHealthcare virtual conferenceWednesday mayOuter membrane protein targeting antibioticsசுவிட்சர்லாந்து ஜநரல்ஹெர்னான் லெவெட்மேரி ஆண்டு சாங்பெர்ன்ஹார்ட் ஸ்கிமிட்சுவிஸ் பரிமாற்றம்சுகாதாரம் மெய்நிகர் மாநாடு